Enchi Liu Selected Research

bapineuzumab

1/2018	Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study.
1/2018	Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab.
10/2016	A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer's disease.
3/2016	First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease.
1/2016	Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis.
1/2016	Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab.
1/2016	Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.
8/2015	Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.
1/2014	Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
8/2012	Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Enchi Liu Research Topics

Disease

21	Alzheimer Disease (Alzheimer's Disease) 01/2018 - 04/2010
5	Edema (Dropsy) 01/2018 - 01/2014
4	Dementia (Dementias) 01/2018 - 08/2015
3	Cognitive Dysfunction 01/2018 - 02/2012
2	Atrophy 09/2013 - 02/2012
1	Pathologic Processes 01/2018
1	Neurobehavioral Manifestations 01/2018
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2018
1	Amyloid Plaque 01/2018
1	Neuroinflammatory Diseases 12/2015

Drug/Important Bio-Agent (IBA)

12	Amyloid (Amyloid Fibrils)IBA 01/2018 - 02/2012
12	bapineuzumabIBA 01/2018 - 04/2010
10	Biomarkers (Surrogate Marker)IBA 01/2018 - 02/2012
9	Monoclonal AntibodiesIBA 01/2018 - 04/2010
4	Apolipoproteins E (ApoE)IBA 01/2018 - 01/2014
3	ApolipoproteinsIBA 01/2018 - 01/2014
3	Pharmaceutical PreparationsIBA 07/2015 - 02/2012
3	Amyloid beta-PeptidesIBA 01/2014 - 04/2010
2	vanutide cridificarIBA 01/2017 - 01/2016
2	saponin QA-21V1 (QS21)IBA 01/2017 - 01/2016
2	VaccinesIBA 01/2017 - 01/2016
1	Proteins (Proteins, Gene)FDA Link 01/2018
1	Biological ProductsIBA 01/2018
1	Fc Receptors (Fc Receptor)IBA 03/2016
1	prothrombin complex concentrates (PPSB)IBA 07/2015
1	2- (4'- (methylamino)phenyl)- 6- hydroxybenzothiazole (Pittsburgh compound B)IBA 04/2010

Therapy/Procedure

4	Therapeutics 01/2016 - 01/2012
2	Immunotherapy 01/2016 - 08/2012
1	Intravenous Infusions 03/2016